galcanezumab

12/01/2023 - "In the 120-mg (approved dose) galcanezumab group, mean change from baseline in weekly migraine headache days was consistent and significantly greater (p < 0.05) than placebo for weeks 1-4; efficacy was consistent when averaged across months 1-6 and in most individual months. "
04/23/2021 - "Post hoc analyses were conducted to determine the efficacy of galcanezumab in patients who had not benefited from six of the most commonly prescribed migraine preventive medications. "
05/28/2021 - "In patients with HFEM, treatment with galcanezumab (120 mg and 240 mg) significantly reduced migraine headache days/month, maintained remission status at subsequent months until the end of the study, and improved patients' quality of life versus placebo. "
03/01/2022 - "Galcanezumab significantly improved functioning and reduced disability in patients with episodic migraine and chronic migraine and two to four migraine preventive treatment category failures. "
03/25/2021 - "Galcanezumab-treated patients had a significantly greater reduction in monthly migraine headache days starting at month 1, which remained significant for all subsequent months compared to placebo (all p ≤ 0.0001, month 1 mean change from baseline: placebo - 0.7; galcanezumab - 4.0). "

01/01/2021 - "In a phase 3 study, galcanezumab significantly reduced the frequency of episodic cluster headache attacks across weeks 1-3 (primary endpoint) compared with placebo. "
06/01/2020 - "In adults with episodic cluster headache, galcanezumab treatment was associated with a significant reduction in the weekly frequency of cluster headache attacks across weeks 1-3 compared with placebo (primary endpoint), albeit during weeks 4-8, there was a convergence of results between these treatment groups. "
02/11/2020 - "300 mg per month galcanezumab is effective for the prevention of episodic cluster headache with no significantly increased adverse events."
03/09/2021 - "In addition, galcanezumab has also been shown to be effective in cluster headache, though more clinical trials are required. "
02/11/2020 - "300 mg per month galcanezumab is effective for the prevention of episodic cluster headache measured by at least 50% reduction of cluster headache frequency at week 3 (RR = 1.36; 95% CI, 1.00-1.84; P = 0.048). "

12/15/2022 - "The efficacy of galcanezumab for both headache and RLS was sustained over 5 months. "
01/01/2022 - "This prospective, observational, multicenter real-life study aimed at investigating the effectiveness of galcanezumab in the first 3 months of treatment of CM patients at 14 Italian headache centers. "
11/23/2023 - "Remarkably, 14.3% of participants reported no longer experiencing any headaches, and 18.9% did not require any acute treatment while receiving galcanezumab treatment. "
10/10/2023 - "The efficacy and safety of galcanezumab were analyzed by comparing daily headache frequency, the number of headache days, and headache intensity and adverse effects during the one-week period before and the third week after galcanezumab injection for each episode of cluster bouts. "
07/01/2023 - "Six patients with HM were treated with galcanezumab in a tertiary-care headache center. "

01/01/2021 - "The reduction from baseline in mean weekly total pain burden was significantly greater with galcanezumab (N=49) than with placebo (N=57): the least squares mean difference was -11.18 severity-weighted hours (p=0.035). "
04/01/2014 - "LY2951742 holds promise for the treatment of pain in OA patients."
12/01/2018 - "This study failed to demonstrate sufficient statistical evidence that galcanezumab was efficacious for treating OA knee pain. "
04/29/2022 - "The present pilot study indicates that Galcanezumab could act on cortical targets located beyond the pain network, restoring the abnormal occipital reactivity. "
01/01/2021 - "Change from baseline in weekly total pain burden across weeks 1-3 was compared between galcanezumab and placebo. "

01/01/2018 - "To demonstrate that galcanezumab is superior to placebo in the prevention of episodic migraine with or without aura. "
02/06/2021 - "Galcanezumab reduced the frequency of migraine headache days with aura in the episodic migraine studies. "
03/16/2023 - "Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders."
03/16/2023 - "The goal of this observational, open-label, cohort study was to determine whether prophylactic migraine treatment with galcanezumab, a peripherally acting drug, alters the incidence of premonitory symptoms, and/or occurrence of headache after exposure to triggers or aura episodes in treatment-responders (≥ 50% reduction in monthly migraine days [MMD]), super-responders (≥ 70%), non-responders (< 50%) and super non-responders (< 30%). "
02/24/2022 - "In this paper, we report two cases of patients suffering from migraine with and without aura, who reported a complete disappearance of aura or reduced aura duration and intensity while taking Galcanezumab or Erenumab, respectively. "